Advances in the use of hydroxyurea
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD. Hydroxyurea has proven clinical efficacy for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome. Salutary effects on hematological parameters include increases in fetal hemoglobin (HbF), hemoglobin, and MCV; also significant decreases occur in WBC, ANC, reticulocytes, LDH, and bilirubin. Treatment with hydroxyurea is usually considered for patients with recurrent vaso-occlusive events, but additional indications for treatment may include laboratory markers of disease severity and evidence of chronic organ dysfunction. Ten years ago, the US Food and Drug Administration approved hydroxyurea for adult patients with clinically severe SCD; however, its use in children remains off-label. Despite the large body of evidence regarding its efficacy and safety, hydroxyurea is currently prescribed only sparingly for patients with SCD and therefore has only limited effectiveness for this disorder; barriers to its use need to be identified and overcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407
Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
Powars, D., Weiss, J., Chan, L., & Schroeder, W. (1984) · Blood · doi:10.1182/blood.v63.4.921.921 · Cited by 314
Cited by
Tsai, M., Kita, A., Leach, J., Rounsevell, R., Huang, J. N., Moake, J., Ware, R. E., Fletcher, D. A., & Lam, W. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58753 · Cited by 297
Self-citationHydroxyurea dose escalation for sickle cell anemia in Sub-Saharan Africa
John, C. C., Opoka, R. O., Latham, T. S., Hume, H. A., Nabaggala, C., Kasirye, P., Ndugwa, C. M., Lane, A., & Ware, R. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2000146 · Cited by 153
Self-citationRecent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
McGann, P. T., Niss, O., Dong, M., Marahatta, A., Howard, T. A., Mizuno, T., Lane, A., Kalfa, T. A., Malik, P., Quinn, C. T., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25510 · Cited by 105
Self-citationEstepp, J. H., Smeltzer, M. P., Kang, G., Li, C., Wang, W. C., Abrams, C., Aygun, B., Ware, R. E., Nottage, K., & Hankins, J. S. (2017) · American Journal of Hematology · doi:10.1002/ajh.24906 · Cited by 88
Self-citation
Metadata
- Authors
- Ware, R. E., & Aygun, B.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2009-01-01
- Volume
- 2009
- Issue
- 1
- Pages
- 62-69
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- OpenAlex
- W2167568609
- Cited by
- 142
- References
- 5
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the use of hydroxyurea. https://app.cochat.ai/papers/10.1182/asheducation-2009.1.62
- The paper
- Ware, R. E., & Aygun, B. (2009). Advances in the use of hydroxyurea. Hematology. https://doi.org/10.1182/asheducation-2009.1.62
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.